



Company Name: BOEHRINGER INGELHEIM PTY LIMITED, VETMEDICA DIVISION
Product Name: VENTIPULMIN ORAL BRONCHODILATOR FOR HORSES
APVMA Approval No: 35958/105303



Label Name:	VENTIPULMIN ORAL BRONCHODILATOR FOR HORSES
Signal Headings:	PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY
Constituent Statements:	16 micrograms/g CLENBUTEROL HYDROCHLORIDE
Claims:	Treatment of bronchospasm and airways obstruction associated with: Bacterial infection - during and after the infective phase Bronchitis Bronchopneumonia Respiratory allergies - e.g. to pollens, fungi, moulds and stable dust Exercise induced bronchospasm All conditions where narrowing of the small airways is a contributing factor to the problem.
Net Contents:	500 g
Directions for Use:	
Restraints:	DO NOT USE in food-producing species of animals.
Contraindications:	This product is contraindicated for use in conjunction with other beta adrenergic agents and in pregnancy at term since uterine contractions may be abolished under its influence.
Precautions:	
Side Effects:	
Dosage and Administration:	2.5 g granules per 50 kg bodyweight twice daily, orally for 10 days (the measure holds 10 g when level).

Horses with chronic bronchoconstriction may require long term continuous bronchodilator therapy. In these cases a lower dose of Ventipulmin (e.g. 1/2 to 2/3 the recommended dose twice daily) may be adequate to produce full control of symptoms.

General Directions:	<p>Properties Ventipulmin is a sympathomimetic amine with selectivity for the beta-2 receptor sites in the body providing bronchodilator properties with minimal effect on the musculature system. Stimulation of beta-2 receptors relaxes the smooth musculature of the bronchi thus resolving bronchial spasm and improving pulmonary ventilation. Ventipulmin is completely absorbed from the gastrointestinal tract following oral administration. It is effective for 6-8 hours after a single dose, 12 hours after repeated twice daily dosing. After treatment for 3-5 days, twice daily administration provides a satisfactory level of medication. Ventipulmin facilitates mucociliary clearance through increased ciliary activity.</p> <p>Clinical experience In clinical trials the effects of Ventipulmin on pulmonary function and clinical response were assessed in horses suffering from a variety of respiratory conditions including chronic obstructive pulmonary disease. The horses responded with a marked decrease in intrathoracic pressure, a decrease in respiratory rate, an initial decrease followed by an increase in arterial oxygen partial pressure and clinical improvement. Other results showed a significant reduction in resistance to airflow and clinical improvement of the animal's respiratory pattern. There were no significant side effects due to the treatment in any of the clinical trials. In those conditions where concurrent infection existed, supplementary treatments with chemotherapeutic agents were instituted.</p>
----------------------------	---

Withholding Periods:	DO NOT USE in horses that may be used for human consumption
-----------------------------	---

Trade Advice:	
----------------------	--

Safety Directions:	
---------------------------	--

First Aid Instructions:	If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131126.
--------------------------------	--

First Aid Warnings:	
----------------------------	--

Additional User Safety:	
--------------------------------	--

Environmental Statements:	
----------------------------------	--

Disposal:	Dispose of empty container by wrapping with paper and putting in garbage.
------------------	---

Storage:	Store below 25 °C (air conditioning) Protect from light
-----------------	--